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Stlmmary 
Candida albicans, an opportunistic fungal pathogen of humans, is dependent upon iron for growth. 
Consequently, human serum inhibits C. albicans growth due to the presence of high af~nity 
iron-binding proteins that sequester serum iron, making it unavailable for use by the organism. 
We report that in the inhibitory environment of human serum, the growth of C. albicans can 
be restored by the addition of exogenous hemoglobin or heme, but not by protoporphyrin IX, 
the heme precursor  that does not contain iron. We further report that C. albicans can utilize 
cell surface proteins that are homolognes of the mammalian complement receptors (CR) to rosette 
complement-coated red blood cells (RBC) and obtain RBC-derived iron for growth. The ability 
of Candida to acquire RBC-derived iron under these conditions is dependent upon Candida-RBC 
rosetting mediated by CR-like molecules. Unopsonized RBC do not support Candicla growth 
in serum, and restoration of Candida growth in serum by comphment-opsonized RBC is inhibited 
by monodonal antibodies to the human CR type 3 (CR3). In addition, activation of the human 
alternative pathway of complement by Candicla leads to "bystander" deposition of C3 fragments 
on the surface of autologous, unopsonized RBC, generating the ligands necessary for Candida- 
RBC rosetting. These results suggest that C. albicans has evolved a unique strategy for acquiring 
iron from the host, which exploits  the host complement system, and which may contribute 
to the pathogenic potential of the organism. 
ndida albicans, a member of the normal human gas- 
intestinal flora, is a major cause of opportunistic fungal 
infection in immunocompromised hosts, especially  those with 
hematologic malignancies (1, 2) and AIDS (3). The complex 
array of factors, both host related (4), and pathogen related 
(5), that are responsible for the virulence of C. albicans under 
these circumstances  have been the subject of considerable  study. 
Factors that have been implicated in the virulence of C. al- 
bicans include the ability of the organism to form germ tubes 
(6, 7), to produce toxins and hydrolytic enzymes (8, 9), and 
to adhere to and invade host tissues (10, 11). 
C. albicans expresses cell surface  proteins that bind C3 degra- 
dation fragments, and as such appear to be functional homo- 
lognes of mammalian complement receptors (CR) (12-15). 
Expression of CR-like molecules by C. albicans was discov- 
ered when it was observed that C. albicans hyphae could ro- 
sette complement-coated sheep erythrocytes (12). The func- 
tion of the Candida CR-like molecules is unknown, but CIL 
expression appears to be associated with the more pathogenic 
species of Candida (12, 13, 16), thus implicating the receptors 
in virulence of the organism. 
C. albicans is growth inhibited in human serum (17-19). 
Although several possibilities have been suggested to account 
for this inhibition (20-22),  a number of reports have cor- 
related inhibition with the presence of transferrin  (18, 23, 
24). Transferrin is a serum protein that binds iron with high 
affinity, restricting free iron to levels  insuf~cient for microbial 
growth (25). Since iron is essential for a variety of cellular 
metabolic processes, pathogenic microorganisms must have 
mechanisms for obtaining iron that is sequestered by the host 
(25). The mechanism(s) by which C. albicans acquires iron 
for growth in the iron-restricted environment of the human 
host have not been extensively investigated. 
Since hemoglobin is  a rich iron  source,  the ability of 
C. albicans to rosette complement-coated RBC led us to in- 
vestigate the possibility  that C. albicans obtains  iron from 
receptor-bound RBC. In the present study we demonstrate 
that C. albicans utilizes hemoglobin from RBC as an iron 
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molecules to bind complement-coated RBC,  allowing the 
fungus to obtain RBC-derived iron for growth. A  mecha- 
nism by which this mode of iron acquisition may occur in 
vivo is suggested by the fact that activation of the alternative 
complement pathway by Candida  cultured in fresh human 
serum leads to deposition on surrounding, autologous RBC 
of  the  C3-derived  ligands  necessary  for  Candida-RBC 
rosetting. 
Materials and Methods 
Iron Compounds.  Fe(NO3)3 (no. F3002), bovine hemoglobin 
(no. H2625), bovine hemin chloride (no. H2250), protoporphyrin 
IX (no. P5889), human  apotransferrin (no. T4515), and human 
holotransferrin (no. T3400) were obtained from Sigma Chemical 
Co. (St. Louis, MO). AU compounds except heroin chloride were 
prepared as stock solutions in water that was deferrated by passage 
through a Chelex filter (Bio-Rad Laboratories, Richmond, CA). 
Hemin chloride was  dissolved in 0.2  M  NaOH prepared with 
Chelex-treated water. 
Candida albicans.  C. albicans strain 13311 (32354; American Type 
Culture  Collection,  Rockville,  MD)  was  passaged weekly  on 
Sabourauds dextrose agar (SDA)  1 plates. Six clinical isolates of 
C. albicans were obtained from Temple  University Hospital (Philadel- 
phia, PA), and were maintained in the same manner as the Amer- 
ican Type  Culture Collection strain. A culture of  yeasts was streaked 
onto a fresh SDA plate 24 h before experiments. 
Assays fir Serum-induced Growth Inhibition Of C  albicans.  Yeast 
phase organisms from 24-h SDA plate cultures were washed with 
sterile saline and resuspended in RPMI 1640 supplemented with 
ghitamine, penicillin, and streptomycin (R.PMI medium) plus the 
indicated concentrations of  heat-inactivated (56~  45 rain) pooled 
normal human  serum (NHS). Yeasts were plated at 250/well in 
polystyrene microtiter dishes and incubated  at  37~  with 5% 
COz. C  albicans cultured under the above conditions convert from 
the yeast to the hyphal form in the presence or absence of human 
serum (26, 27). The extent of hyphal growth after 18 h of culture 
was determined by [3H]glucose  uptake assay (26, 27) and by MTT 
assay (28). 
[~H]Glucose Uptake Assay.  Assay  for Candida hyphal growth by 
uptake of  radiohbded glucose has been described  in detail elsewhere 
(26, 27). Briefly, after 18 h of growth under the described ex- 
perimental conditions, medium was removed, wells were washed 
with sterile distilled water, and 25 #1 of 2,5[3H]glucose (Net-807, 
sp act 67 Ci/mMol; New England Nuclear, Boston, MA), diluted 
to 10 #Ci/ml in sterile water, was added to each well. Plates were 
incubated for 30 min at 37~  25 #1 bleach was added to wells 
to remove  phstic-adherent hyphae, and radiohbeled C. albicans were 
harvested onto glass fiber filters using an automatic cell harvester. 
Radioactivity incorporated into C  albicans hyphae, which is propor- 
tional to the amount of hyphal growth (26, 27), was counted in 
a liquid scintillation counter. 
MTTAssay.  Quantitation of Candida growth by tetrazolium- 
based colorimetric assay was performed as described by Lavitz and 
Diamond (28). Microtiter wells containing adherent Candida hyphae 
1 Abbreviations usedin thisl~atx,  r: CSds, CS-deficient  serum; HRBC, human 
red blood  ceUs; NHS, normal  human serum; RRBC, rat red blood cells; 
SDA, Sabourauds dextrose agar. 
grown for 18 h under the described experimental conditions were 
washed twice with sterile water and 5 #g/well of MTT (3-[4,5- 
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium  bromide;  M2128; 
Sigma Chemical Co.), diluted in RPMI 1640 without phenol red 
(Gibco Laboratories, Grand Island, NY) was added for 4 h at 37~ 
Conversion of MTT to insoluble  MTT-formazan  by Cand/da-derived 
dehydrogenases was  quantitated  after  solubilization  of MTT- 
formazan with 10% SDS and warm acid alcohol. The change in 
OD at 570 nm was determined using a microELISA reader. 
SRBC Opsonization.  RBC obtained from fresh, heparinized 
sheep blood were washed three  times with  HBSS, adjusted to 
105/ml in HBSS containing 1:150 anti-SRBC IgM (Diamedix Co., 
Miami, FL), and incubated for 30 rain at 23~  with shaking. IgM- 
coated SRBC were washed twice with HBSS and incubated for 
20 rain at 37~  in HBSS +  10% C8-deficient serum (C8ds) for 
complement deposition. C8ds was obtained from a C8-deficient 
donor, as previously described (29). Cells were washed twice and 
incubated for an additional 15 rain at 37~  in HBSS +  5% heat- 
inactivated  CSds to convert remaining C3b to iC3b. Previous  studies 
have shown that using this protocol for opsonization, the predom- 
inant form of C3 on the RBC surface is iC3b (D. M. Mosser, un- 
published data).  Complement-coated  SRBC were washed three 
times and adjusted to the desired concentration in RPMI medium 
for addition to (2. albicans cultures. Unopsonized SRBC underwent 
the same incubations without the addition of antibody and C8ds. 
Rosetting of SRBC to C  albicans.  105 C. albicans hyphal colo- 
nies grown in suspension for 18 h in RPMI medium  +  0.25% 
NHS  were  washed  and  cultured  with  10  s  unopsonized  or 
complement-opsonized SRBC. After 1 h at 37~  an aliquot of 
hyphae was taken and examined microscopically  for Candida-SRBC 
rosetting. To assay for C. albicans growth in the presence of RBC, 
250 yeast phase organisms were cultured in microtiter wells as de- 
scribed above, in RPMI medium supplemented with 0.25% heat- 
inactivated NHS. Medium was removed from wells and comple- 
ment-opsonized or unopsonized SRBC diluted in RPMI medium 
plus 5% heat-inactivated C8ds were added to the wells at the indi- 
cated concentrations. In these assays, heat-inactivated C8ds is used 
as a source of transferrin to create an iron-restricted environment. 
After culture for an additional 18 h at 37~  the extent of hyphal 
growth was determined by uptake of 3H-glucose. 
mAll  LPM19c  and 14B6E.2, mAbs specific  for the human CR3 
a chain (CDllb) (30) and R6.5, a mAb specific  for ICAM-1, were 
generou~y provided  by Dr. T. A. Springer (Harvard Medical School,. 
Boston, MA). mAb to human iC3b neoantigen was obtained from 
Quidd (San Diego, CA). 
Pre~ration  of Radiolakeled Rat  RBC  (RRBC).  SgFe-hbeled 
RRBC were obtained from anemic Sprague-Dawley  rats according 
to the method described by Pippard et al. (31). SgFe-labeled  RRBC 
were opsonized using the method described for SRBC, except red 
cells were coated with anti-RRBC IgM, 1:1,500  dilution, (Accurate 
Chemical Co., Westbury, NY) before the deposition  of  complement. 
Assar for Uptake of Iron from Radiolabeled RRBC by C. albicans 
H2/phae.  2  x  104  yeasts  were  cultured  in  polypropylene 
microfuge  tubes  at 37~  in  RPMI medium  plus 0.25% heat- 
inactivated NHS. After 18 h, hyphae were washed and incubated 
for an additional 2 h with 107 complement-opsonized or unop- 
sonized SgFe-RRBC diluted in RPMI medium plus 2.5%  heat- 
inactivated CSds. Hyphae were washed with HBSS + 0.1% BSA, 
followed by three washes with water to lyse RRBC, and a final 
wash with HBSS-BSA to remove unincorporated radiolabd.  The 
amount of SgFe taken  up after  2 h  by C.  albicans hyphae was 
counted in a gamma counter. 
"~Bystander" Rosetting of Human RBC (HRBC)  to C.  albicans. 
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Figure 1.  Inhibition of C. albicans growth by human serum. (A) C. albicans was grown 
in RPMI medium as described in Materials and Methods, in the presence of increasing con- 
centrations of NHS (circles), 10 #g/ml apotransferrin (open  square), or 250 #g/ml holotrans- 
ferrin (open diamond). The extent of hyphal growth after 18 h of culture was quantitated 
by uptake of [3H]glucose (open  symbols) and by MTT assay (filled  circles). Results shown are 
representative of six experiments and are expressed as cpm •  SD of [3H]glucose taken up 
by triplicate wells of C  albicans or as the absorbance at 570 nm•  SD of MTT-formazan 
from triplicate cultures. (B) Photomicrographs  of C  albicans  grown in 5%, 0.25%, and 0.05% 
heat-inactivated NHS. Similar results were obtained with six clinical isolates of C. albicans 
(data not  shown). 
5  x  103 yeasts were cultured in individual wells of 96-well mi- 
erotiter dishes at 37~  in RPMI medium plus 0.25% NHS. After 
18 h, medium was removed and 5  x  106 HRBC diluted in 50/~1 
RPMI medium plus 10% autologous fresh serum, heat-inactivated 
serum, C3-depleted serum, or fresh serum treated with EDTA or 
EGTA/Mg  2+ were added to the wells.  After 1 h  at 37~  wells 
were washed gently three times to remove excess unbound HRBC 
and cultures were scored blindly for the presence of C. albicans- 
HRBC rosettes. For a quantitative assay of rosetting, the amount 
of hemoglobin associated with C. atbi~ns-HRBC rosettes was mea- 
sured.  5  x  103 (7,. albicans yeasts were grown in RPMI medium 
with 0.25% NHS for 18 h in 1.5-ml microcentrifuge tubes. Medium 
was removed and hyphae were resuspended in a 50-/~1 volume of 
serum plus 2.5  x  107 HRBC. After 1 h at 37~  200/~1 medium 
was added and the tubes were incubated for an additional  I h, during 
which  time nourosetted  HRBC  settled into  a pellet below the 
hyphae. Hyphae were carefully removed to fresh tubes without dis- 
turbing the unbound RBC pellet, washed once, and resuspended 
in water to lyse bound RBC. The amount of hemoglobin released 
by bound RBC was measured by determining the absorbance at 
420 nm. 
Flow C),tometry.  HRBC for flow cytometry analysis were ob- 
tained from rosetted and nourosetted cultures containing C  albicans 
hyphae and fresh or heat-inactivated  autologous serum, respectively. 
Wells were washed three times gently to remove excess unbound 
HRBC from the wells, fo[iowed by more vigorous washing to re- 
move remaining rosetted and nonrosetted HRBC. Cells obtained 
in this manner were assayed for the presence of complement by 
incubating for 45 min on ice with a 1:15 dilution of monoclonal 
anti-iC3b followed by goat anti-mouse Ig-FITC (National Cancer 
Institute Repository, Bethesda,  MD).  C. albicans hyphae, which 
are firmly adherent to plastic, are not removed from the wells by 
this procedure. Fluorescence analysis was performed on a FACScan  | 
analyzer (Becton Dickinson &  Co.). 
Results 
Inhibition of C. albicans Growth in Human Serum and Resto- 
ration  of Growth  by Ferric Nitrate and Hemoglobin.  Growth 
of C. albicans hyphae was dramatically inhibited in the pres- 
ence of increasing concentrations  of heat-inactivated  NHS, 
as indicated by a  dose-dependent  decrease in the uptake of 
radiolabded glucose into hyphae (Fig.  1 A). Serum-induced 
growth inhibition was also reflected by a dose-dependent de- 
crease in the reduction of MTT to MTT-formazan by C. al- 
1645  Moors et al. b/cans, as well as by colony size (Fig.  1, A  and B). This in- 
hibitory effect  was reproduced by substituting  10 #g/ml 
purified human apotransferrin  for  serum  in  the  growth 
medium (Fig. 1 A). The addition of up to 250 #g/ml iron- 
saturated holotransferrin, in contrast, did not inhibit Can- 
dida growth. Furthermore, inhibition of Candida growth in 
5% serum could be completely reversed by the addition of 
increasing concentrations of ferric  nitrate  to  the  growth 
medium (Fig. 2), indicating that serum-induced growth in- 
hibition is the result of iron restriction. 
To determine if Candida could utilize hemoglobin as an 
iron source, medium containing 5% serum was supplemented 
with increasing concentrations of hemoglobin or heme, the 
iron-containing moiety of hemoglobin (Fig. 2). Both hemo- 
globin and heme restored Candida growth in serum. Protopor- 
phyrin IX, the heme precursor that does not contain iron, 
did not, however,  support Candida growth. 
Taken together, these results indicate that growth inhibi- 
tion of C. albicans hyphae in human serum is due to iron 
restriction, and that C. albicans grown under these condi- 
tions is unable to effidently access iron bound by transferrin. 
Iron from hemoglobin, however, is accessible to Candida and 
restores  hyphal growth in serum. 
Complement-Opsonized SRBC Rosette C  albicans Hyphae and 
Restore C  albicans Growth in Serum.  Since hemoglobin is se- 
questered in RBC, heme-derived iron is generally inacces- 
sible to pathogenic microorganisms. We hypothesized that 
C. albicans has a mechanism for obtaining heme-derived iron 
from RBC, and that this mechanism involves binding of RBC 
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Figure 2.  C. albicans can utilize heme-derived iron for growth in human 
serum.  (2. albicans was grown as described in Materials and Methods in 
RPMI medium supplemented with 5% NHS  +  equimolar concentra- 
tions of hemoglobin (filled circles), heme (open circles), protoporphyrin  IX 
(PPIX) (filled squares),  or Fe(NO3b (open squares). After 18 h at 37~ 
the extent of C. albicans growth was quantitated by uptake of [3H]glu- 
cose. Results shown are representative of five  experiments and are expressed 
as cpm  •  SD of radiolabeled glucose  taken up by triplicate  wells of 
C.  albicans. 
to Candida via CR-like molecules.  To test this, C. albicans 
hyphae were cultured for 18 h in the presence of SRBC op- 
sonized with complement. Hyphae formed rosettes with op- 
sonized SRBC (Fig. 3 A), but not unopsonized SRBC (Fig. 
3 B), after 1 h in culture. If binding of RBC to complement 
receptors on Candida enables the organism to obtain RBC- 
derived iron, it would be expected that opsonized, but not 
unopsonized, SRBC would restore Candida growth in serum. 
As shown in Fig. 3 C, in the presence of serum, unopsonized 
SRBC have a minimal effect on Candida growth, but hyphal 
growth in serum is increased  15-50-fold when opsonized 
SRBC are added to the cultures. Rosetting of opsonized SRBC 
to hyphae, therefore,  results in enhanced growth of C. al- 
bicans in human serum. 
mAbs to Human CR3 Block Opsonized SRBC.induced Growth 
ofC albicans in Serum.  Others have shown that certain mAbs 
to the human CR3 cx chain (CDllb) react with C. aibicans 
(13, 15, 32). When C. albicans hyphae were preincubated with 
two anti-human CR3 mAbs, LPM19c and 14B6E.2, roset- 
ring to iC3b-coated SRBC was inhibited (data not shown), 
and the capacity of complement-coated  SRBC to restore Can- 
dida growth in serum was dramatically decreased (Fig.  4). 
The two antibodies in combination almost completely reversed 
the opsonized SRBC-induced growth of Candida in serum. 
An isotype-matched control mAb, R6.5, which is specific 
for ICAM-1, had no effect on opsonized SRBC-induced Can- 
dida growth. Candida growth in iron-sufficient  medium, in 
the absence of serum and SRBC, was not inhibited by mAbs 
to the CR3 (Fig. 4, legend). These results indicate that binding 
of RBC to Candida hyphae via surface CR-like molecules en- 
hances growth of the organism under conditions of iron limi- 
tation. 
Uptake of SgFe  from Complement-opsonized, Rodiolabded RBC. 
To demonstrate directly that C. albicans is able to obtain iron 
from RBC bound to complement receptors,  RRBC were 
radiolabded in vivo with SgFe, and the uptake of radiolabeled 
iron by iron-deprived Candida was measured. As shown in 
Fig. 5, Candida grown in serum acquired significantly more 
radiolabeled  iron from opsonized than from unopsonized 
RRBC. Moreover,  uptake of iron from opsonized RRBC 
was inhibited by antibodies to the human CK3. We con- 
dude, therefore, that C. albicans has a mechanism for obtaining 
heme-derived iron from RBC and that binding of RBC to 
CR-like molecules on Candida is  a  requisite step in  this 
mechanism. 
"Bystander' Deposition of C3 Fragments on RBC as a Result 
of  Alternative Pathway Activation by C. albicans.  For Candida 
to utilize the above mechanism for iron acquisition in the 
human host, the C3-derived ligands for Candida CR-like mol- 
ecules must be present on HRBC. Others have shown that 
activation of complement can lead to deposition of C3 frag- 
ments not only on the surface of the complement activator 
itself, but also on host tissues in the vicinity of activation 
(33, 34). Indeed, complement activation by C. albicans was 
found to lead to deposition of complement  components along 
the basement membranes in cutaneous lesions of patients with 
chronic mucocutaneous  candidiasis (35). We hypothesized that 
in the presence of fresh human serum, complement would 
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Figure 3.  Rosetting of  complement-coated  SRBC to 
hyphar restores growth of C  albicans in human serum. 
C. albicans hyphae cultured for 1 h with complement- 
opsonized  (/1) or unopsonized  (B) SR.BC. (C) (2. albicans 
hyphar were incubated for 18 h with increasing doses 
of  SR.BC (opsonized  or unopsonized)  in medium + 5% 
CSds as described  in Materials  and Methods, and growth 
in triplicate  walls was quantitated  by uptake of [3H]glu- 
cose. Results shown  are representative of three ex- 
periments. 
become deposited on autologous RBC by a "bystander" mech- 
anism after activation of the alternative complement pathway 
(36) by C. albicans.  To test this hypothesis, we cultured Can- 
dida hyphae with HRBC in the presence of fresh autologous 
serum or serum treated to inactivate complement. After 1 h 
at 37~  the cultures were examined for Candida-RBC  ro- 
settes. In addition, rosetting was measured spectrophotometri- 
caUy by the amount of hemoglobin released after water lysis 
of bound HRBC.  Rosetting occurred in all wells in which 
the alternative complement pathway was  intact,  including 
wells that received fresh, autologous serum and serum treated 
with EGTA/Mg  a+  (Table 1).  Rosetting did not occur under 
conditions  in which  the alternative pathway was  rendered 
nonfunctional,  including  serum  that  was  exposed  to  heat 
(56~  45  rain),  treated with  EDTA,  or immunologically 
depleted of C3  (Table 1).  Photomicrographs  of C.  albicans 
cultured with HRBC and fresh or heat-inactivated serum are 
shown in Fig. 6. These results indicate that in an autologous 
human system, activation of the alternative pathway of com- 
plement by C.  albicans  can lead to complement deposition 
on  "bystander"  tLBC,  and  consequently  to  Candida-RBC 
rosetting. 
To show directly that C3 degradation fragments may be- 
come deposited on HRBC as a result of alternative pathway 
activation by Candida, HRBC that were washed from rosetted 
and nonrosetted wells were analyzed by flow cytometry for 
the presence of surface C3 fragments using a mAb  specific 
for human iC3b. A  significant percentage of HRBC washed 
from rosetted wells  (those that  received fresh serum),  but 
not  nourosetted wells  (those that  received heat-inactivated 
1647  Moors et al. 
Figure 4.  mAbs  to human CR3 inhibit SRBC(op)-indueed  growth of 
C. albicans in human serum. Growth assay was performed as in Fig. 3, 
except hyphae were prdncubated for 30 min at 37~  with 4/~g/well of 
anti-CR3 mAbs LPM19c  and 14B6E.2, or control mAb R6.5 (anti-ICAM- 
1). lOS/well  opsonized  SRBC were added for 1 h, wells were washed free 
of nonrosetted RBC, and cultures were incubated for 18 h in media con- 
taining 5% CSds. Hyphal growth was quantitated by uptake of [3H]g]u- 
cose. Results shown are from one of two experiments and are expressed 
as cpm  +  SD of radiolabded glucose taken up by triplicate samples of 
C  albicans. In a separate  experiment, C albicans grown for 18 h in RPMI 
medium alone yielded 57,081 +  2,219 Clan; C albicans grown in RPMI 
medium +  4/~g/well LPM19c  yielded 53,276 +  1,000 cpm; and C. al- 
bicans grown in RPMI medium + 4/~g/well 14B6E.2  yielded 70,482 + 
6,795 epm. Table  1.  Rosetting  as a Result  of Alternative Pathway 
Activation by C. albicans 
Serum  R.osetting  OD4~ 
Fresh  +  t.39  _+  0.38 
Heat inactivated  -  0.12  _+  0.01 
C3 depleted  -  0.04  _+  0.03 
Fresh  +  EDTA  -  0.02  +_  0.03 
(10 mM) 
Fresh  +  EGTA/Mg  2§  +  1.59  _+  0.27 
(10 raM/10 mM) 
Figure 5.  C albicans  hyphae  take  up radiohbeled  iron  from  complement- 
coated PdLBC. C. albicans were cultured  with opsonized  or unopsonized 
59Fe-labeled RRBC as described  in Materials  and Methods. In one sample, 
hyphae  were  preineubated  for 30 min at 37~  with 4/xg/well  anti-human 
CR3 mAb LPM19c  before addition  of opsonized RRBC. Results  are ex- 
pressed as cpm of S9Fe taken up by C. albicans. Results shown are from 
one of three experiments. In three independent  experiments, the ratio of 
cpm taken  up by C. albicans  from  opsonized  KRBC  compared  with unop- 
sonized RRBC ranged from 3 to 10. 
serum), were positive for bound human iC3b (Fig. 7). These 
results  indicate  that  activation  of the  human  alternative 
pathway by Candida in the presence of HRBC leads to depo- 
sition of the ligands for Candida  CR-like molecules on the 
surface of host ILBC by a "bystander" mechanism, resulting 
in Candicla-RBC  rosetting. 
Discussion 
Molecules that mimic mammalian complement-binding 
proteins are expressed by various pathogenic microorganisms. 
Expression of CR-l-like molecules by HSV (37, 38) and EBV 
(39), and of a decay-accelerating factor-like protein by Trypano- 
soma cruzi (40),  have been previously reported. In each case 
it has been speculated that these molecules facilitate survival 
in  the  host,  possibly  by  interfering  with  host  comple- 
ment-mediated lysis  (38-41).  Expression  of complement- 
binding molecules on C. albicans has also been demonstrated 
(12,  13). Since these proteins represent potential virulence 
factors of the organism (12, 13, 16), it is of interest to deter- 
mine their function(s). 
The human host presents potential pathogens with a highly 
iron-restricted  environment. As a result of their need for iron, 
pathogenic microorganisms have adapted a variety of mecha- 
nisms for obtaining host-derived iron (25,  42-44).  In fact, 
the possession of an efficient mechanism for obtaining host- 
derived iron is a factor that has been shown in some systems 
to distinguish virulent from avirulent bacterial strains (25). 
To access iron from the host, many bacteria and fungi pro- 
duce siderophores, low molecular weight molecules with high 
c. albicans hyphae  were cultured  with HRBC and 10% fresh  autologous 
serum, heat-inactivated  (56~  45 min) serum, serum  depleted  immuno- 
logically  of C3, or serum chelated  with EDTA, or EGTA/Mg  2+ . Af- 
ter 1 h at 37~  cultures  were scored  blindly  for Candida-HRBC rosettes 
( + / - ). In addition,  rosetting  is expressed as the amount  of hemoglobin 
associated with HRBC bound  to Candida, and was determined  by meas- 
uring the absorbance  of hemoglobin  at 420 nm as described  in Materials 
and Methods. Results are representative of three experiments. 
iron-binding affinities. These molecules are able to compete 
successfuUy  with host iron-binding proteins for elemental iron 
(25). In addition, some bacteria obtain iron from transferrin 
by directly binding transferrin-iron complexes  (43),  while 
others have the ability to utilize heine-containing compounds 
(44-46). 
Numerous studies have demonstrated serum-induced growth 
inhibition of C. albicans (17-22).  In these studies, inhibition 
was attributed to a variety of factors  (20-22),  however,  a 
number of reports have related serum-induced growth inhi- 
bition to the presence of transferrin (18, 23, 24). In the latter 
studies it was demonstrated that growth inhibition could be 
reversed by the addition of exogenous iron. These studies in- 
dicated that iron is necessary for the growth of C. albicans. 
The mechanism(s) by which C. albicans acquires iron for sur- 
vival in the iron-limiting environment of the human host 
are largely unknown. 
In the present report we propose a novel mechanism by 
which C. albicans may obtain iron for growth in the human 
host, which involves the use of CR-like molecules. Specifically, 
we have shown that expression  by C. albicans of a molecule 
with iC3b-binding activity enables the organism to bind host 
RBC and obtain heme-derived iron for growth. Evidence 
to support this model is as follows: (a)  C.  albicans hyphae 
rosette complement-opsonized, but not unopsonized RBC; 
(b)  in the presence  of inhibitory concentrations of serum, 
growth of C. albicans is increased  up to 50-fold as a result 
of Candida-RBC rosetting. Unopsonized, non-rosetted RBC 
have little effect on Candida  growth in serum; (c) rosetting 
of Candicla to complement-opsonized RBC is inhibited by 
monoclonal antibodies to the human CR3. Inhibition of roset- 
ting correlates with inhibition of opsonized SRBC-induced 
Candida growth; (e) rosetting of hyphae to opsonized, radio- 
labeled RBC results in the uptake of radiolabeled iron by Can- 
1648  Candicla  Complement  Receptors and Iron Acquisition Figure 6.  Activation of the alternative pathway of complement by (3. albicans results in "bystander" deposition of complement on autologous RBC. 
Photomicrographs  of Candida hyphal colonies that were cultured for 1 h as described in Materials and Methods with HRBC  +  10% fresh autologous 
serum (.4) or heat-inactivated autologous  serum (B). 
dida. Radiolabeled iron uptake is inhibited by antibodies to 
the human CR3. 
That unopsonized RBC do not restore Candida growth 
in the manner observed with opsonized RBC indicates that 
dose contact between C.and/ah  and RBC, mediated  by a specific 
receptor-ligand interaction, is a necessary prerequisite for up- 
take of RBC-derived iron by Candida. The importance of 
this interaction for uptake of RBC-derived iron is further 
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Figure 7.  iC3b is present on HRBC cultured with C  albicans  and fresh 
autologous serum. HRBC obtained as described in Materials and Methods 
from rosetted and noarosetted CandiaG cultures were stained with anti- 
human  iC3b mAb followed by goat anti-mouse  Ig FITC-conjugated  anti- 
body and analyzed by flow microfluorimetry  for iC3b expression. The 
dashed line  represents the goat anti-mouse  Ig FITC control, the solid line 
represents heat-inactivated  serum, and the dotted line r~presents  fresh serum. 
R~sults shown are representative of four experiments. 
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substantiated by the blocking of this process by mAbs to the 
human CR3 (Figs. 4 and 5).  The events that occur subse- 
quent to Candida-RBC  binding and before iron uptake are 
presently unknown, and are currently under investigation. 
Preliminary data,  however,  suggest the involvement of a 
Candida-derived hemolysin in this process  (D.  M.  Mosser, 
unpublished data). 
The production of siderophores by C. albicans has been 
reported (42, 47), but the conditions under which Candida 
utilizes these molecules have not been described in detail. 
It  is  clear  that  in  our  system,  however,  Candida-derived 
siderophores do not function e~ciently (Fig. 1). C. albicans, 
in addition to being a potential pathogen, is a commensal 
organism in the human gut, where an abundance of nutrients, 
including elemental iron, are available as a result of digestive. 
processes. It is possible that under circumstances such as these, 
in which iron is not bound by transferrin, that Candida-derived 
siderophores operate to scavenge  iron. Acquisition of iron from 
RBC by the mechanism that we describe may be important 
in disseminated candidiasis, at sites of invasive infection such 
as kidney and liver, where elemental iron is not readily avail- 
able and where there is an abundance of RBC. In addition, 
C. albicans may utilize this mechanism in mucocutaneous le- 
sions in which the organism has penetrated the superficial 
layers of the skin resulting in an inflammatory response (35, 
48). It is likely that the ability to utilize more than one mech- 
anism for iron acquisition, depending upon the local envi- 
ronment, would contribute to the pathogenic versatility  of 
the organism. 
The method of iron acquisition that we propose would 
be dependent upon the presence of the CR3 ligand, iC3b, 
on the surface of host RBC. It is a well described phenomenon 
that complement activation can lead not only to deposition 
of complement component C3b on the surface of the com- 
plement activator,  but also in the fluid phase (49)  and on the surface of surrounding host tissues  (33, 34). In lesions 
of patients with chronic mucocutaneous candidiasis (35),  as 
well as in an experimental animal model (48), C3 fragments 
were detected on the surface of host tissues as well as on the 
surface of C, albicans as a result of complement activation. 
Similarly, we have shown that activation of the alternative 
complement pathway by C. albicans can result in deposition 
of C3 fragments on the surface of surrounding autologous 
RBC (Figs.  6 and 7).  Once deposited by this "bystander" 
effect, C3b would become degraded by serum factors H and 
I to its inactive form, iC3b, the CR3 ligand. Moreover, this 
process would be facilitated by the presence of CR1 on HRBC 
(50).  CR1 has factor I cofactor activity for the conversion 
of C3b to iC3b, and further to C3dg (50),  a fragment that 
has  also  been shown to bind  Candida  CR-like  molecules 
(12-14). 
Others have proposed that the Candida CR3, like the mam- 
malian CR3, which is a member of the integrin family of 
proteins (51), functions as an adhesion molecule, promoting 
the adherence of Candida  to host tissues  (16, 52). The host 
tissue ligand for this interaction, however, has not been de- 
termined. In light of the data presented here, the possibility 
that C3 degradation fragments may also serve as adherence 
ligands for Candida CR-like molecules deserves consideration. 
In summary, we propose a novel mechanism of iron acqui- 
sition by C. albicans, which involves the use of molecules that 
mimic host complement receptors. In addition, we show that 
C. albicans can utilize hemoglobin horn RBC as an iron source. 
To our knowledge, this is the first report of the utilization 
of a heine-containing compound as an iron source by a patho- 
genic fungus. We are currently investigating whether C. al- 
bicans acquires RBC-derived iron by a hemoglobin receptor, 
similar to certain bacteria (T. L. Stull, unpublished results). 
The predisposition of certain immunocompromised  patients 
to infection with C. albicans is clearly a result of host factors 
such as leukocyte defidendes and prolonged exposure to 
chemotherapeutic agents (4). However, the ability of C. al- 
bicans to persist in mucocutaneous and disseminated lesions 
may be facilitated by the ability of the organism to exploit 
the host  complement system to  acquire and utilize  host 
RBC-derived iron. The use of CR-like molecules for iron 
acquisition by C. albicans may therefore be an important vir- 
ulence factor of the organism. 
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